Shots:

• The EC’s approval is based on data from DELIVER and REFINE studies evaluating the efficacy- PK- and PD of Tysabri (300mg- SC- q4w) vs Tysabri (300mg- IV- q4w) in patients with RRMS
• The results demonstrated that the Tysabri (SC) in both studies showed clinical benefits and well-characterized safety profile. The SC option expands the clinical settings while safety is consistent with IV formulation in other clinical studies and the post-marketing setting
• Tysabri is the only high-efficacy MS therapy to offer two routes of administration options thus- providing flexibility to meet patients' individual preferences and needs

  Ref: GlobeNewswire | Image: Biogen